What's in Beijing InnoCare Pharma Tech Co., Ltd.'s pipeline?

Beijing InnoCare Pharma Tech Co., Ltd. has 22 drugs in our index: 0 marketed, 0 filed, 7 in Phase 3, 5 in Phase 2, 10 in Phase 1.

Which companies overlap with Beijing InnoCare Pharma Tech Co., Ltd.'s portfolio?

Top competitors by shared drug class: AstraZeneca, Pfizer, Sun Yat-sen University, Nanfang Hospital, Southern Medical University, Betta Pharmaceuticals Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/beijing-innocare-pharma-tech-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Beijing InnoCare Pharma Tech Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Beijing InnoCare Pharma Tech Co., Ltd. pipeline: 0 marketed, 0 filed, 7 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 7 Phase 3 5 Phase 2 10 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
ICP-488	ICP-488	phase 3	FLT3 inhibitor	FLT3	Oncology
ICP-022	ICP-022	phase 3	Bruton's tyrosine kinase (BTK) inhibitor	BTK (Bruton's tyrosine kinase)	Oncology
ICP-332 Tablets	ICP-332 Tablets	phase 3	Tyrosine kinase inhibitor		Oncology
Placebo + R-CHOP	Placebo + R-CHOP	phase 3	Monoclonal antibody + multi-agent chemotherapy combination	CD20 (rituximab component); multiple targets (CHOP chemotherapy)	Oncology
Orelabrutinib and R-CHOP	Orelabrutinib and R-CHOP	phase 3	BTK inhibitor	BTK	Oncology
ICP-488 Tablets	ICP-488 Tablets	phase 3	EGFR tyrosine kinase inhibitor	EGFR (epidermal growth factor receptor)	Oncology
Orelabrutinib + R-CHOP	Orelabrutinib + R-CHOP	phase 3	BTK inhibitor, chemotherapy regimen	Bruton's tyrosine kinase (BTK)	Oncology

Therapeutic area mix

Oncology · 7

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 4 shared drug classes
Pfizer · 3 shared drug classes
Sun Yat-sen University · 2 shared drug classes
Nanfang Hospital, Southern Medical University · 2 shared drug classes
Betta Pharmaceuticals Co., Ltd. · 2 shared drug classes
Pharmacyclics LLC. · 2 shared drug classes
Genzyme, a Sanofi Company · 2 shared drug classes
Aurigene Discovery Technologies Limited · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Beijing InnoCare Pharma Tech Co., Ltd.:

Cite this brief

Drug Landscape (2026). Beijing InnoCare Pharma Tech Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/beijing-innocare-pharma-tech-co-ltd. Accessed 2026-05-16.